Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity
Saved in:
Main Authors: | Jae Hyun Bae, Young Min Cho |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-02-01
|
Series: | Journal of Diabetes Investigation |
Online Access: | https://doi.org/10.1111/jdi.14336 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Beyond incretins: targeting neurokinin receptors for obesity treatment
by: Doreen Thor, et al.
Published: (2025-01-01) -
Incretin hormone agonists as promising antiobesity drugs - review of literature
by: Aleksandra Grzegorczyk, et al.
Published: (2025-01-01) -
Bile acids and incretins as modulators of obesity-associated atherosclerosis
by: Andrijana Kirsch, et al.
Published: (2025-01-01) -
The Application of Incretin-Based Pharmacotherapy in the Contemporary Management of Type 2 Diabetes: A Review of the Literature
by: Jakub Waszczyński, et al.
Published: (2025-01-01) -
Maintaining Fat-Free Mass and Muscle Mass during obesity therapy with Incretin-Mimetic Drugs
by: Dariusz Popiela, et al.
Published: (2025-01-01)